Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Free Cash Flow for 6 consecutive years, with -$7.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 40.6% to -$7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.8 million through Dec 2025, down 45.18% year-over-year, with the annual reading at -$27.8 million for FY2025, 45.18% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$7.5 million at Inhibikase Therapeutics, up from -$10.6 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$2.0 million in Q3 2021, with the low at -$10.6 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$4.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 145828.38% in 2021, then surged 35.25% in 2024.
  • Over 5 years, Free Cash Flow stood at -$4.1 million in 2021, then grew by 13.17% to -$3.6 million in 2022, then increased by 3.2% to -$3.4 million in 2023, then crashed by 55.28% to -$5.3 million in 2024, then crashed by 40.6% to -$7.5 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$7.5 million, -$10.6 million, and -$5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.